 Home > Biochemistry News > Biotechnology News > Innovative FGFR inhibitor for the treatment of cholangiocarcinoma was granted priority review by the FDA

Innovative FGFR inhibitor for the treatment of cholangiocarcinoma was granted priority review by the FDA

 Last Update: 2022-05-22
 Source: Internet
 Author: User

Tags

standard identity fda

lithium drug interactions

food early pregnancy

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Today, Japan’s Taiho Pharmaceutical and its subsidiary Taiho Oncology announced that the U.

Cholangiocarcinoma includes intrahepatic and extrahepatic cholangiocarcinoma, and it usually occurs in the elderly

Futibatinib inhibits FGFR-mediated signaling by irreversibly covalently binding to the ATP-binding "pocket" of FGFR1-4, thereby reducing the proliferation of tumor cells harboring FGFR1-4 genetic variants

▲Schematic diagram of the mechanism of action of Futibatinib (Image source: Reference [2])

The filing is based on data from a pivotal Phase 2b clinical trial in which 103 patients received futibatinib

"This is an important step toward our goal of bringing futibatinib to patients in need of new treatment options,

References:

[1] US Food and Drug Administration (FDA) Accepts for Priority Review Taiho Oncology's New Drug Application for Futibatinib for Cholangiocarcinoma.

[2] Sootome et al.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express for the treatment of cholangiocarcinoma, innovative FGFR inhibitor has been granted priority review by the FDA

04-28

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Innovative FGFR inhibitor for the treatment of cholangiocarcinoma was granted priority review by the FDA

Related Articles

Express for the treatment of cholangiocarcinoma, innovative FGFR inhibitor has been granted priority review by the FDA